Aging Liver Clearance of Amyloid-Beta Restored in Rats
Early rat study suggests a new research direction for Alzheimer's, though it has not been tested in humans or disease models.
Updated on Nov. 6, 2026 in Diseases

Researchers at the University of Southern California restored liver clearance function in aged rats using the experimental drug cinaciguat, with blood levels of amyloid-beta 40 falling by half in treated animals, according to a study published in the Journal of Biological Chemistry. The work is preclinical and is limited to rats, so it does not yet tell readers anything about human treatment.
Why it matters
Amyloid-beta circulating in the blood is partly removed by the liver, and that clearance weakens with age, which makes the liver a possible target for the broader question of how amyloid builds up in aging bodies. The study points to a new line of inquiry for Alzheimer's researchers, but it did not show that treatment reduces brain plaques, improves memory, or prevents the disease.
This is a preclinical study in aged rats that gave two-year-old animals daily cinaciguat for two weeks, with three to six independent biological samples per condition. Blood amyloid-beta 40 fell by half and LDL cholesterol dropped, but the work does not yet show benefits for the brain or memory.
The players
University of Southern California
A major research university whose researchers led this study on liver clearance of amyloid-beta in aging.
The details
Cinaciguat reopened microscopic openings in the vessel-lining cells of the liver, which had become smaller and fewer with age. It also restored release of the growth factor HB-EGF from older vessel-lining cells, renewing their communication with the liver's hepatocytes, and restored surface levels of two substance-capturing proteins.
Timeline
Daily cinaciguat dosing of two-year-old rats ran for two weeks in the study.
Health Landscape
Much of Alzheimer's research has focused on the brain, so a finding that the liver's ability to clear circulating amyloid-beta declines with age adds a peripheral angle to the field. Any path to a human therapy would still require animal disease models and later clinical testing of related drugs.
This is an early laboratory result in rats, so it does not change any current screening, treatment, or prevention decisions. Readers concerned about memory or Alzheimer's risk should keep discussing those questions with their physician.
The takeaway
The liver's role in clearing amyloid-beta from the blood appears to weaken with age, which makes this a promising new research direction rather than a treatment. Readers who want to understand their own memory or Alzheimer's risk should talk with their doctor about current evidence-based steps.
Further reading
For broader context on how researchers are studying the condition, see Alzheimer’s coverage in California.





